EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Treatment of Ulcerative Colitis—From Conventional Therapies to Targeted Biologics and Small Molecules

Aleksandra Wilk iD, Mateusz Pawłowski iD, Ewa Balcerczak iD, Agnieszka Jeleń iD, Marek Mirowski iD, Dagmara Szmajda-Krygier iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031534 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Aleksandra Wilk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: statutory funds of the Department of Pharmaceutical Biochemistry and Molecular Diagnostics, the Medical University of Lodz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The goals of ulcerative colitis (UC) treatment are focused on improving quality of life, achieving steroid-free remission, and minimizing the risk of cancer. In UC traditional management, a step-up strategy involves introducing increasingly more immunosuppressive medications, thus avoiding unnecessary overexposure to more potent drugs. However, in cases of severe, acute UC, priority is rapid and effective treatment to minimize the risk of complications such as bleeding, intestinal perforation, toxic megacolon or the need for colectomy. Modern approach to UC management shifts to an “accelerated step-up” or “top-down” approach in high-risk patients to prevent bowel damage. A holistic approach—integrating molecular research, clinical management and patient-centered care—enhances our understanding of disease mechanisms and therapeutic strategies, ultimately supporting improved outcomes and overall quality of life. This review aims to present the treatment options for UC along with an overview of the most modern therapies and experimental agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansQuality of LifeAnimalsMolecular Targeted TherapyImmunosuppressive Agents

Stichwörter der Autor:innen

inflammatory bowel diseasenovel biologic drugssmall moleculesulcerative colitis

Substanzen

Biological ProductsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
  • BRaIn Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.

ORCID-Profile: Aleksandra Wilk, Mateusz Pawłowski, Ewa Balcerczak, Agnieszka Jeleń, Marek Mirowski, Dagmara Szmajda-Krygier

Förderung

  • statutory funds of the Department of Pharmaceutical Biochemistry and Molecular Diagnostics, the Medical University of Lodz

Zitieren

APA

Wilk, A., Pawłowski, M., Balcerczak, E., Jeleń, A., Mirowski, M., & Szmajda-Krygier, D. (2026). Advances in the Treatment of Ulcerative Colitis—From Conventional Therapies to Targeted Biologics and Small Molecules. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031534

Vancouver

Wilk A, Pawłowski M, Balcerczak E, Jeleń A, Mirowski M, Szmajda-Krygier D. Advances in the Treatment of Ulcerative Colitis—From Conventional Therapies to Targeted Biologics and Small Molecules. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031534

BibTeX
@article{Wilk2026,
  author = {Wilk, Aleksandra and Pawłowski, Mateusz and Balcerczak, Ewa and Jeleń, Agnieszka and Mirowski, Marek and Szmajda-Krygier, Dagmara},
  title = {Advances in the Treatment of Ulcerative Colitis—From Conventional Therapies to Targeted Biologics and Small Molecules},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031534}
}
Kostenlos starten →